US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
pharma · Atopic Dermatitis · Acne Vulgaris
UAS Pharmaceuticals Pty
Galderma Australia Pty Ltd
UAS Pharmaceuticals Pty drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Castle Hill, AU HQ
2000 Founded
44 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Castle Hill, AU
- Founded
- 2000
- Employees
- 44
- Programs
- 4
- Drugs
- 7
- Patents
- 0
UAS Pharmaceuticals Pty pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
UAS Pharmaceuticals Pty drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to UAS Pharmaceuticals Pty in public FDA and regional records.
-
Development asset linked to UAS Pharmaceuticals Pty in public FDA and regional records.
-
Development asset linked to UAS Pharmaceuticals Pty in public FDA and regional records.
-
Development asset linked to UAS Pharmaceuticals Pty in public FDA and regional records.
-
nemolizumab
Dermatologicals (D11)Dermatologicals (D11) compound in UAS Pharmaceuticals Pty's portfolio. Molecular target: Interleukin-31 receptor subunit alpha.
- Target
- Interleukin-31 receptor subunit alpha
- Mechanism
- Interleukin-31 receptor subunit alpha inhibitor
-
Development asset linked to UAS Pharmaceuticals Pty in public FDA and regional records.